ABSTRACT

In this talk, I will present an overview of our precision medicine program leveraging genomics and AI to deliver high-quality, outcomes-changing personalized medicine to cancer patients at Weill Cornell Medicine. I will describe our effort to bring whole-genome sequencing into the clinic, automate the interpretation of genomes and more broadly use whole-genome sequencing as a platform for AI-driven predictive medicine. I will also describe orthogonal techniques to obtain new insights into clinical samples, such as single-cell tissue imaging using imaging mass cytometry, and describe the application of this technology coupled with analytics to turn millions of single cells into cancer subtypes that predict treatment response. In an effort to help augment the number of effective therapies targeting alterations we see in cancer patients, I will then discuss ongoing projects using AI  to help develop novel therapies, focusing initially on predicting mechanisms of action of orphan molecules and positioning them in specific patient populations. I will finish by outlining some important future directions for AI in precision medicine.

SPEAKER

Olivier Elemento is a professor of physiology and biophysics at Weill Cornell Medicine (WCM) and Cornell University. Since 2017, he has been the Director

of the Caryl and Israel Englander Institute for Precision Medicine (https://eipm.weill.cornell.edu/). The Englander Institute is a multidisciplinary institute that

draws over 100 faculty members from nearly all basic and clinical departments at Cornell University. The Englander Institute’s mission is to use genomics,

artificial intelligence (AI), patient-derived models and other technologies to develop and bring highly personalized medicine to patients at Weill Cornell’s

affiliated hospital, NewYork Presbyterian Hospital (NYPH) and elsewhere. The Institute also fosters patient-centered basic and clinical research in the areas

of genomics, systems biology, AI and data science. Dr. Elemento is funded by numerous NIH grants, foundation grants, NIH contracts and industry

alliances. He has published over 360 papers in the area of precision medicine, genomics, computational biology, artificial intelligence, systems biology

and drug discovery. Dr. Elemento co-founded two venture capital-funded companies, Volastra Therapeutics and OneThree Bio.

Add event on Google Calendar

Add event on Outlook